Clinical trial
GEMOX: Oxaliplatin in Pancreatic Cancer
NCT00261092 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00261092 |
|---|---|
| Title | GEMOX: Oxaliplatin in Pancreatic Cancer |
| Official title | Phase II Multicenter, Open Label Study of Oxaliplatin Combined With Gemcitabine(GEMOX) in Advanced and Metastatic Pancreatic Cancer |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug |
| Interventions | Oxaliplatin |
| Enrollment | 48 |
| Start date | Oct 1, 2005 |
| First posted | Dec 2, 2005 |
| Last update posted | Apr 15, 2008 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: